Sponsors (12)
The bill improves drug supply-chain transparency and speeds recalls/import processes—helping patient safety and supply reliability—but imposes compliance costs, possible short-term availability disruptions, and some legal/oversight trade-offs for manufacturers, importers, and customs.
Patients (especially those with chronic conditions) and hospitals can more reliably verify drug origin and traceability because finished-drug labels (or linked portals) must identify original API manufacturers, finished-product manufacturers, and packers/distributors.
Hospitals, pharmacies, and supply managers get clearer supply-chain information through required unique facility identifiers and electronically available manufacturer data, improving inventory management and procurement transparency.
Recalls and safety investigations can be faster and more accurate because labels include original manufacturers and unique facility identifiers, reducing time-to-action for dangerous or contaminated products.
Drug manufacturers, packers, and distributors will face new compliance costs to add unique facility identifiers, change labeling, and maintain searchable portals, which could be passed on in prices or strain smaller firms.
Hospitals and patients risk short-term supply disruptions because older inventory or in‑transit drugs may need relabeling or could be temporarily unavailable while firms update labels to comply.
Requiring publication of unique facility identifiers and manufacturer locations could raise commercial confidentiality and security concerns for some firms, potentially exposing sensitive business data.
Based on analysis of 3 sections of legislative text.
Requires drug labels and many API shipments to identify original API manufacturers and facility identifiers (or provide scannable links) and lets FDA-compliant labeling satisfy Customs origin marking for finished drugs.
Introduced February 5, 2026 by Richard Lynn Scott · Last progress February 5, 2026
Requires finished drug labels and many active pharmaceutical ingredient (API) shipments to identify the manufacturing establishment(s) by name, place of business, and a unique facility identifier (or provide a scannable link to that data); finished products must also identify the original manufacturer(s) of each API and the finished-product manufacturer/packer/distributor. Also makes FDA-compliant drug labeling the operative country-of-origin marking for imported finished drug products, exempting them from the general Customs marking rules. Directs the HHS Secretary to write implementing regulations (allowing reasonable alternatives including electronic placements) and sets a compliance timeline no earlier than one year after those regulations are published. The change is aimed at improving supply-chain transparency, traceability for recalls and inspections, and simplifying Customs marking for imported drugs, while imposing new labeling and electronic reporting duties on manufacturers, packers, distributors, and importers.